Quart Barry D's Form 4 filing
Kiniksa Pharmaceuticals International, plcKNSA · filed Dec 1, 2022
- Accession no.
- 0001415889-22-011878
- Filed
- Dec 1, 2022
- Trade date
- Nov 29, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $354.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Quart Barry DCIK 0001384243 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2022 | Class A Common Share | MOption exerciseAcquired | +21,959 | $1.59 | +$34,914.81 | 21,959 | Direct | |
| Nov 29, 2022 | Class A Common Share | SSaleDisposed | −21,959 | $16.15F1 | −$354,637.85 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2022 | Class A Common Share | MOption exerciseDisposed | −21,959 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $16.09 to $16.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Class A Common Shares sold at each price.
Referenced by the price of 1 transaction in Table I.